Join
Live feed
·
PRReleasevia Quantisnow
Arcutis Biotherapeutics Inc. logo

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARQT (Arcutis Biotherapeutics Inc.) and more on Quantisnow.